Literature DB >> 19718063

Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning.

E Willems1, F Baron, L Seidel, P Frère, G Fillet, Y Beguin.   

Abstract

The role of conditioning intensity on occurrence of thrombotic microangiopathy (TMA) after allogeneic hematopoietic cell transplantation (HCT) has remained unclear thus far. Here, we retrospectively compared the incidence of TMA in patients given allogeneic hematopoietic stem cells after either nonmyeloablative (n=176) or high-dose (n=111) conditioning. The 1-year cumulative incidence of TMA was 13% in nonmyeloablative recipients versus 15% in high-dose conditioning recipients (P=0.5). In multivariate Cox analysis, occurrence of grade 3-4 acute graft-versus-host disease (GVHD) (hazard ratio (HR)=2.3, P<0.001), older age (HR=1.01, P=0.045), and unrelated donors (HR=1.6, P=0.01) were each associated with a higher risk of TMA, whereas nonmyeloablative conditioning was associated with a lower risk of TMA (HR=0.6, P=0.01). We conclude that acute GVHD, age, donor type, and conditioning intensity might have a role in the physiopathology of TMA after allogeneic HCT.

Entities:  

Mesh:

Year:  2009        PMID: 19718063     DOI: 10.1038/bmt.2009.230

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  21 in total

1.  NCI, NHLBI/PBMTC first international conference on late effects after pediatric hematopoietic cell transplantation: endocrine challenges-thyroid dysfunction, growth impairment, bone health, & reproductive risks.

Authors:  Christopher C Dvorak; Clarisa R Gracia; Jean E Sanders; Edward Y Cheng; K Scott Baker; Michael A Pulsipher; Anna Petryk
Journal:  Biol Blood Marrow Transplant       Date:  2011-10-17       Impact factor: 5.742

2.  Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus.

Authors:  J Labrador; L López-Corral; O López-Godino; L Vázquez; M Cabrero-Calvo; R Pérez-López; M Díez-Campelo; F Sánchez-Guijo; E Pérez-López; C Guerrero; I Alberca; M C Del Cañizo; J A Pérez-Simón; J R González-Porras; D Caballero
Journal:  Bone Marrow Transplant       Date:  2014-02-24       Impact factor: 5.483

Review 3.  Hematopoietic stem cell transplant-associated thrombotic microangiopathy: current paradigm and novel therapies.

Authors:  J Khosla; A C Yeh; T R Spitzer; B R Dey
Journal:  Bone Marrow Transplant       Date:  2017-10-02       Impact factor: 5.483

4.  The potential role of HLA-DRB1*11 in the development and outcome of haematopoietic stem cell transplantation-associated thrombotic microangiopathy.

Authors:  K Balassa; H Andrikovics; P Remenyi; A Batai; A Bors; K P Kiss; A Szilvasi; K Rajczy; D Inotai; L Gopcsa; L Lengyel; A Barta; M Reti; A Tordai; T Masszi
Journal:  Bone Marrow Transplant       Date:  2015-07-06       Impact factor: 5.483

5.  A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant.

Authors:  Christopher E Dandoy; Seth Rotz; Priscila Badia Alonso; Anna Klunk; Catherine Desmond; John Huber; Hannah Ingraham; Christine Higham; Christopher C Dvorak; Christine Duncan; Michelle Schoettler; Leslie Lehmann; Maria Cancio; James Killinger; Blachy Davila; Rachel Phelan; Kris M Mahadeo; Sajad Khazal; Nahal Lalefar; Madhav Vissa; Kasiani Myers; Greg Wallace; Adam Nelson; Pooja Khandelwal; Deepika Bhatla; Nicholas Gloude; Eric Anderson; Jeffrey Huo; Philip Roehrs; Jeffery J Auletta; Ranjit Chima; Adam Lane; Stella M Davies; Sonata Jodele
Journal:  Blood Adv       Date:  2021-01-12

6.  Impact of Thrombotic Microangiopathy on Renal Outcomes and Survival after Hematopoietic Stem Cell Transplantation.

Authors:  Merve Postalcioglu; Haesook T Kim; Faruk Obut; Osman Arif Yilmam; Jiqiao Yang; Benjamin C Byun; Sophie Kupiec-Weglinski; Robert Soiffer; Jerome Ritz; Joseph H Antin; Edwin Alyea; John Koreth; Corey Cutler; Philippe Armand; Julie M Paik; David E Leaf; Vincent T Ho; Reza Abdi
Journal:  Biol Blood Marrow Transplant       Date:  2018-05-11       Impact factor: 5.742

7.  Brain microvascular endothelial cells exhibit lower activation of the alternative complement pathway than glomerular microvascular endothelial cells.

Authors:  Sarah E Sartain; Nancy A Turner; Joel L Moake
Journal:  J Biol Chem       Date:  2018-03-19       Impact factor: 5.157

Review 8.  A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury.

Authors:  Sonata Jodele; Benjamin L Laskin; Christopher E Dandoy; Kasiani C Myers; Javier El-Bietar; Stella M Davies; Jens Goebel; Bradley P Dixon
Journal:  Blood Rev       Date:  2014-11-28       Impact factor: 8.250

Review 9.  Transplant-associated thrombotic microangiopathy: opening Pandora's box.

Authors:  E Gavriilaki; I Sakellari; A Anagnostopoulos; R A Brodsky
Journal:  Bone Marrow Transplant       Date:  2017-03-13       Impact factor: 5.483

10.  Thrombotic Microangiopathy after Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.

Authors:  Philip H Imus; Hua-Ling Tsai; Amy E DeZern; Kevin Jerde; Lode J Swinnen; Javier Bolaños-Meade; Leo Luznik; Ephraim J Fuchs; Nina Wagner-Johnston; Carol Ann Huff; Douglas E Gladstone; Richard F Ambinder; Christian B Gocke; Syed Abbas Ali; Ivan M Borrello; Ravi Varadhan; Robert Brodsky; Richard J Jones
Journal:  Biol Blood Marrow Transplant       Date:  2020-09-19       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.